Difference between revisions of "Clear cell renal cell carcinoma"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
Line 55: Line 55:
  
 
=== From Cosmic Mutated in >20% ===
 
=== From Cosmic Mutated in >20% ===
 +
 +
[[VHL]] (43%), [[PBRM1]] (30%)
 +
 
=== Mutated in 10-20% ===
 
=== Mutated in 10-20% ===
=== Mutated in 5-10% ===  
+
 
 +
[[BAP1]] (11%), [[SETD2]] (11%)
 +
 
 +
=== Mutated in 5-10% ===
 +
 
 +
[[KDMC5]] (6%), [[TP53]] (5%)
 +
 
 
=== Mutated in 2-5% ===  
 
=== Mutated in 2-5% ===  
=== mtDNA ===  
+
 
 +
[[PTEN]], [[KMT2C]], [[AKAP9]], [[KMT2D]], [[TERT]], [[RANBP2]], [[PIK3CA]], [[ATM]], [[ARID1A]], [[CDKN2A]], [[SRGAP3]], [[SMARCA4]], [[MLLT4]], [[TCF12]]
 +
 
 +
=== mtDNA ===
  
 
== Epigenomics (methylation) ==
 
== Epigenomics (methylation) ==

Revision as of 20:53, 12 February 2016

Contributors

Daynna Wolff PhD FACMG

Tumor Type

Renal Cell Carcinoma

Tumor Classification

Clear Cell RCC

This tumor type accounts for 70-75% of all renal cell carcinoma cases (citation needed).

Description

Malignant epithelial cells with clear cytoplasm and a compact-alveolar (nested) or acinar growth pattern interspersed with intricate, arborizing vasculature. A variable proportion of cells with granular eosinophilic cytoplasm may be present. Infrequently, clear cell renal cell carcinoma has a distinct tubular pattern and rarely a pseudopapillary architecture is focally present."

IHC Markers

Positive: vimentin, CD10, RCC, PAX2, PAX8, CA-IX, EMA

Negative: CK7, CD117, AMACR, E-cadherin

Genomic Gain/Loss/LOH

Chromosome Gain/Loss/Amp Region
1 Loss 1p
3 Loss 3p (3p21, 3p25 and/or 3p13-p14)
4 Loss 4q
5 Gain 5q
8 Loss 8p
9 Loss 9p, 9q
14 Loss 14q

Rearrangements

Write your comments here

Mutations (SNV/INDEL)

Write your comments here

From Cosmic Mutated in >20%

VHL (43%), PBRM1 (30%)

Mutated in 10-20%

BAP1 (11%), SETD2 (11%)

Mutated in 5-10%

KDMC5 (6%), TP53 (5%)

Mutated in 2-5%

PTEN, KMT2C, AKAP9, KMT2D, TERT, RANBP2, PIK3CA, ATM, ARID1A, CDKN2A, SRGAP3, SMARCA4, MLLT4, TCF12

mtDNA

Epigenomics (methylation)

Write your comments here

Main Pathways Involved

Write your comments here

Clinical Significance

Write your comments here

Diagnosis

Write your comments here

Prognosis

Write your comments here

Therapeutics

Write your comments here

Familial Forms

Write your comments here

References